Antares Pharma to Present at the Jefferies Global Healthcare Conference
May 31 2012 - 7:00AM
Business Wire
Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Paul
K. Wotton, Ph.D., President and Chief Executive Officer, will
present at the 2012 Jefferies Global Healthcare Conference on
Thursday June 7, 2012 at 3:00 pm Eastern Time.
A live webcast of the presentation will be available via the
“Investor Relations” page of the Antares website,
www.antarespharma.com. A replay of the webcast will also be
archived on Antares’ website for 90 days following the
presentation.
About Antares Pharma
Antares Pharma focuses on self-injection pharmaceutical products
and topical gel-based medicines. The Company's subcutaneous and
intramuscular injection technology platforms include Vibex™
disposable pressure-assisted auto injectors, disposable multi-use
pen injectors and Vision™ reusable needle-free injectors marketed
as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva)
and Ferring Pharmaceuticals (Ferring), respectively. In the
injector area, Antares Pharma has a multi-product deal with Teva
that includes Tev-Tropin® human growth hormone (hGH) and a
partnership with Ferring that includes Zomacton® hGH. In the
gel-based area, the Company's FDA approved product is Gelnique 3%™
for the treatment of OAB (overactive bladder) which has been
licensed to Watson Pharmaceuticals, Inc. for marketing in the U.S.
and Canada. Antares’ portfolio includes Elestrin® (estradiol gel)
indicated for the treatment of moderate-to-severe vasomotor
symptoms associated with menopause, and marketed in the U.S. by
Jazz Pharmaceuticals. Antares Pharma has two facilities in the U.S.
The Parenteral Products Group located in Minneapolis, Minnesota
directs the manufacturing and marketing of the Company’s reusable
needle-free injection devices and related disposables, and develops
its disposable pressure-assisted auto injector and pen injector
systems. The Company’s corporate offices and Pharma Group are
located in Ewing, New Jersey, where pharmaceutical products are
developed utilizing both the Company’s transdermal systems and
drug/device combination products.
Antares (AMEX:AIS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares (AMEX:AIS)
Historical Stock Chart
From Jul 2023 to Jul 2024
